Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-01-09 06:59 |
Number of shares and voting rights of IPH as at January 5, 2017
|
English | 68.4 KB | ||
| 2017-01-04 07:00 |
CP en français
|
French | 73.2 KB | ||
| 2017-01-04 07:00 |
PR in English
|
English | 72.1 KB | ||
| 2017-01-04 07:00 |
PR in English
|
English | 70.3 KB | ||
| 2017-01-04 07:00 |
CP en français
|
French | 70.6 KB | ||
| 2016-12-19 07:00 |
IPH annonce des évolutions dans son management et sa gouvernance
|
French | 90.1 KB | ||
| 2016-12-19 07:00 |
IPH announces key leadership and corporate governance change
|
English | 89.3 KB | ||
| 2016-12-05 07:00 |
Données cliniques pour lirilumab et IPH4102 à l'ASH2016
|
French | 121.3 KB | ||
| 2016-12-05 07:00 |
Further clinical data for lirilumab and IPH4102 presented at ASH 2016
|
English | 125.5 KB | ||
| 2016-11-30 10:15 |
PR in English
|
English | 101.4 KB | ||
| 2016-11-30 10:15 |
CP en français
|
French | 103.6 KB | ||
| 2016-11-12 17:15 |
SITC 2016 : Présentation de données cliniques
|
French | 131.0 KB | ||
| 2016-11-12 17:15 |
SITC 2016 : Clinical Data Release
|
English | 157.6 KB | ||
| 2016-11-10 07:00 |
InnInvestor conference call on November 14, 2016
|
English | 98.0 KB | ||
| 2016-11-10 07:00 |
Conférence téléphonique investisseur le 14 nov. 2016
|
French | 101.9 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
